Zimmer Biomet Holdings, Inc. $ZBH Stock Purchased by Grandfield & Dodd LLC

Grandfield & Dodd LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 80.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,823 shares of the medical equipment provider’s stock after buying an additional 9,284 shares during the period. Grandfield & Dodd LLC’s holdings in Zimmer Biomet were worth $1,818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ZBH. Citizens National Bank Trust Department increased its position in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 141 shares during the last quarter. Leonteq Securities AG boosted its position in Zimmer Biomet by 5.3% in the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after purchasing an additional 153 shares during the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of Zimmer Biomet by 1.6% in the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after buying an additional 175 shares during the last quarter. Glenview Trust Co boosted its stake in shares of Zimmer Biomet by 3.7% during the 3rd quarter. Glenview Trust Co now owns 5,067 shares of the medical equipment provider’s stock worth $450,000 after acquiring an additional 179 shares during the last quarter. Finally, Corbyn Investment Management Inc. MD grew its holdings in Zimmer Biomet by 0.5% during the first quarter. Corbyn Investment Management Inc. MD now owns 34,050 shares of the medical equipment provider’s stock valued at $3,079,000 after purchasing an additional 183 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 3.0%

Shares of Zimmer Biomet stock opened at $94.54 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm’s 50-day moving average is $94.86 and its two-hundred day moving average is $91.70. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $103.70. The stock has a market cap of $18.03 billion, a price-to-earnings ratio of 23.00, a PEG ratio of 2.27 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $2.07 earnings per share. Zimmer Biomet’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Transactions at Zimmer Biomet

In other news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The SEC filing for this sale provides additional information. 1.28% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZBH. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Barclays upgraded Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Truist Financial upped their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Finally, Stifel Nicolaus raised their price target on Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.